TD Cowen Maintains a Hold on Genmab A/S (GMAB)

Genmab A/S (NASDAQ:GMAB) is one of the most profitable biotech stocks to invest in now. In a report released on July 14, Yaron Werber from TD Cowen maintained a Hold rating on Genmab A/S (NASDAQ:GMAB) without a price target.

In other news, Genmab A/S (NASDAQ:GMAB) reported on July 16 that net sales of DARZALEX totaled $3.539 billion in Q2 2025, with net trade sales of $ 2.017 billion in the US and $1.521 billion in the rest of the world.

Genmab A/S (NASDAQ:GMAB) receives royalties on the global net sales of DARZALEX, both the intravenous and SC products, under the exclusive worldwide license to Johnson & Johnson for the manufacturing, development, and commercialization of daratumumab.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases.

Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

While we acknowledge the potential of GMAB as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.